SCHEMBL8626082

SCHEMBL8626082

CCCCCCCCCCCCCCCOCC(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.69
EPHX2 P34913 1/20 0.58
PAM P19021 2/20 0.53
PLA2G4B P0C869 2/20 0.51
GPR84 Q9NQS5 7/20 0.50
PPARG P37231 6/20 0.50
PPARD Q03181 6/20 0.50
PPARA Q07869 6/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
ALDH1A1 P00352 2/20 0.50
TLR2 O60603 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 2/20 0.50
FABP4 P15090 2/20 0.50
PTPN1 P18031 2/20 0.50
KMT2A Q03164 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
SLC22A8 Q8TCC7 1/20 0.50
ESR1 P03372 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4651569 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL7249862 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL8198788 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL501889 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL1603697 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL21611691 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL7763197 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL3296171 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL21611665 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL7611940 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048037-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN EPITRACKER INC (US) 2026-02-19 US disclosed
US-12440473-B2 Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain Epitracker, Inc. (US) 2025-10-14 US disclosed
US-11951088-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome Epitracker, Inc. (US) 2024-04-09 US disclosed
US-20230399298-A1 ACID ADDITION SALT OF INDENE DERIVATIVE PRODRUG AND METHOD FOR PREPARING SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-12-14 US disclosed
US-20230303491-A1 DONEPEZIL ETHER PALMITATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-09-28 US disclosed
EP-4238963-A1 ACID ADDITION SALT OF INDENE DERIVATIVE PRODRUG AND METHOD FOR PREPARING SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2023-09-06 EP disclosed
CN-116685574-A Acid addition salts of indene derivative prodrugs and methods of making same 株式会社钟根堂 2023-09-01 CN disclosed
EP-4198021-A1 DONEPEZIL ETHER PALMITATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Chong Kun Dang Pharmaceutical Corp. (KR) 2023-06-21 EP disclosed
CN-116018140-A Donepezil Ji Mi palmitate or pharmaceutically acceptable salts thereof 株式会社钟根堂 2023-04-25 CN disclosed
WO-2022092813-A1 ACID ADDITION SALT OF INDENE DERIVATIVE PRODRUG AND METHOD FOR PREPARING SAME 주식회사 종근당 2022-05-05 WO disclosed
WO-2022035048-A1 DONEPEZIL ETHER PALMITATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 주식회사 종근당 2022-02-17 WO disclosed
EP-3934639-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN Epitracker, Inc. (US) 2022-01-12 EP disclosed
US-20210386710-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN Epitracker, Inc. 2021-12-16 US disclosed
US-20210386710-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN Epitracker, Inc. 2021-12-16 US disclosed
US-10792266-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome Epitracker, Inc. (US) 2020-10-06 US disclosed
US-10792266-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome Epitracker, Inc. (US) 2020-10-06 US disclosed
US-20190117607-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME Epitracker, Inc. 2019-04-25 US disclosed
US-20190117607-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME Epitracker, Inc. 2019-04-25 US disclosed
EP-0844099-A1 Heat-sensitive recording material FUJI PHOTO FILM CO., LTD. (JP) 1998-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303491-A1 DONEPEZIL ETHER PALMITATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF NAPEPLD, PSEN1, CETP CES2 198/4885EPHX2 787/4885PAM 2314/4885
US-20190117607-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME FABP1, FASN, GPR119 CES2 1954/4885EPHX2 3189/4885PAM 2295/4885
US-20210386710-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN SCD, FABP7, ELOVL1 CES2 205/4885EPHX2 1687/4885PAM 1815/4885
US-10792266-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome FABP1, FASN, GPR119 CES2 1954/4885EPHX2 3189/4885PAM 2295/4885
US-20230399298-A1 ACID ADDITION SALT OF INDENE DERIVATIVE PRODRUG AND METHOD FOR PREPARING SAME IDE, NOTUM, PSEN1 CES2 144/4885EPHX2 446/4885PAM 1759/4885
US-11951088-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome FABP1, FASN, GPR119 CES2 1954/4885EPHX2 3189/4885PAM 2295/4885
US-20260048037-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN CNR1, CNR2, FFAR1 CES2 133/4885EPHX2 1451/4885PAM 2850/4885
US-12440473-B2 Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain SCD, FABP7, ELOVL1 CES2 205/4885EPHX2 1687/4885PAM 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.